Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab.

Patients who presented with intermediate MRD and carried a TP53 aberration showed a trend for shorter median PFS compared with patients without TP53 aberrations who achieved the same MRD levels (30 vs 40 months, P =0.42, Supplementary Figure 2a ).

also in 53,322 other papers